FindTrial
Sign In

To Study The Efficacy Of Vallipanchamula Churna In The Management Of Madhumeha w.s.r To Type 2 Diabetes Mellitus.

Efficacy Of Vallipanchamula Churna In The Management Of Madhumeha w.s.r To Type 2 Diabetes Mellitus - An Open Labeled Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043141
Enrollment
50
Registered
2022-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Government Akhandanand College And Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Classical signs and symptoms of Madhumeha- PrabhutaavilaMutrata, pipasadhikya, kshudhadhikya, swedadhikya, Nidradhikya, karapadataladaha, karapadatalasuptata, angagandha, daurbalya, shrama, galatalushosha, tandra 2)Fasting plasma glucose upto 200 mg/dl and post prandial glucose level upto 300mg/dl 3)Both insulin dependent and non insulin dependent type 2 diabetes mellitus patients will be included 4)Both newly diagnose and patients on allopathic treatment will be included in this study

Exclusion criteria

Exclusion criteria: 1)Patients with other metabolic and endocrinal disorders. 2)Patients having uncontrolled blood sugar. 3)Fasting plasma glucose level more than 200mg/dl & post prandial glucose level more than 300mg/dl will be excluded 4)Patients having any other malignancies, any other systemic / serious illness. 5)Patients with diabetic wound / ulcers. 6)Patients of Diabetes mellitus Type 1 (Juvenile Diabetes). 7)Patients having acute & serious complications of Type 2 Diabetes Mellitus. 8)Patients with Coronary artery disease, Peripheral vascular disease & cerebrovascular disease & 9)Other chronic debilitating disease like STD, Tuberculosis etc. 10)Pregnant women

Design outcomes

Primary

MeasureTime frame
Improvement in laboratory investigations like FBS,PPBS.Timepoint: 2 weeks after completion of treatment.—

Secondary

MeasureTime frame
Improvement in sign and symptoms of Madhumeha (Type 2 Diabetes Mellitus) like prabhutavila mutrata, pipasadhikya, kshudhadhikya, swedadhikya, Nindradhikya, karapadataladaha, karapadatalasuptataTimepoint: 2 weeks after completion of treatment.—

Countries

India

Contacts

Public ContactDr Anamika S Soni

GOVERNMENT AKHANDANAND AYURVEDA COLLEGE AND HOSPITAL

ayursoni@yahoo.com9269533108

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026